Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?

Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bo, Wood, Laura S., James, Karen, Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621341/
https://www.ncbi.nlm.nih.gov/pubmed/26550505
http://dx.doi.org/10.1155/2015/817578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621341/
https://www.ncbi.nlm.nih.gov/pubmed/26550505
http://dx.doi.org/10.1155/2015/817578

Ejemplares similares